| PRECLINICAL | evidence | Incretin polyagonists as an alternative to bariatric surgery to manage obesity. | Tirzepatide | — | 2026-03-22 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. | Tirzepatide | — | 2026-03-21 |
| PRECLINICAL | evidence | The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives. | Tirzepatide | — | 2026-03-20 |
| PRECLINICAL | evidence | Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy. | Tirzepatide | — | 2026-03-20 |
| PRECLINICAL | evidence | New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication. | Mounjaro | Weight & fat loss | 2026-03-18 |
| PRECLINICAL | evidence | Euglycemic diabetic ketoacidosis following treatment with tirzepatide and SGLT-2 inhibitors: A case report and literature review. | Tirzepatide | — | 2026-03-17 |
| PRECLINICAL | evidence | Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report. | Mounjaro | — | 2026-03-16 |
| PRECLINICAL | evidence | Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. | Tirzepatide | Glycemic control | 2026-03-14 |
| PRECLINICAL | evidence | GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. | Tirzepatide | Weight & fat loss | 2026-03-13 |
| PRECLINICAL | evidence | [Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)]. | Tirzepatide | Sleep quality | 2026-03-12 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations. | Tirzepatide | — | 2026-03-11 |
| PRECLINICAL | evidence | Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. | Tirzepatide | Glycemic control | 2026-03-11 |
| PRECLINICAL | evidence | Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure. | Tirzepatide | Weight & fat loss | 2026-03-10 |
| PRECLINICAL | evidence | Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing's syndrome: a multicenter retrospective study. | Tirzepatide | Glycemic control | 2026-03-10 |
| PRECLINICAL | evidence | Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage. | Tirzepatide | — | 2026-03-10 |
| PRECLINICAL | evidence | Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG? | Tirzepatide | — | 2026-03-09 |
| PRECLINICAL | evidence | Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation. | Tirzepatide | Glycemic control | 2026-03-09 |
| PRECLINICAL | evidence | A bibliometric analysis of systematic reviews and meta-analyses on diabetes mellitus: global research trends from scopus database (1988-2024). | Tirzepatide | — | 2026-03-06 |
| PRECLINICAL | evidence | Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. | Tirzepatide | Glycemic control | 2026-03-05 |
| PRECLINICAL | evidence | Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF. | Tirzepatide | Lipid & cardiovascular markers | 2026-03-03 |
| PRECLINICAL | evidence | Redefining Obstructive Sleep Apnea: Treatment in the Modern Era. | Tirzepatide | — | 2026-03-02 |
| PRECLINICAL | evidence | Lipedema and Dynapenia: Inflammatory Myosteatosis as a Mechanistic Link Between Tissue Expansion and Muscle Dysfunction. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Tirzepatide-Induced Liver Injury: A Rare Complication. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Effect of Tirzepatide on Cardiovascular Outcomes. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Metabolic advances in 2025: from clinical breakthroughs to molecular reprogramming. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Tirzepatide a major breakthrough in treatment of obstructive sleep apnoea. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Tirzepatide as adjunct to insulin for the treatment of type 1 diabetes. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity. | Tirzepatide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | THR-beta Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Tirzepatide-induced body composition changes: Implications from the SURPASS-3 MRI substudy. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document. | Tirzepatide | Lipid & cardiovascular markers | 2026-03-01 |
| PRECLINICAL | evidence | Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Bariatric Surgery in the Era of GLP1RA: A Narrative Review. | Tirzepatide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial. | Tirzepatide | Weight & fat loss | 2026-03-01 |